Friday, 14 August 2020

Preview of Biologics World Korea 2013

07 December 2012 | News | By BioSpectrum Bureau

Biologics World Korea 2013 will be held from April 16-18, 2013, in Seoul, South Korea

Biologics World Korea 2013 will be held from April 16-18, 2013, in Seoul, South Korea

Singapore: Biologics World Korea, which attracted over 130 biologics industry leaders in 2012, has decided to conduct the 2013 edition of the event from April 16-18, 2013, at the Sheraton Incheon Hotel in Seoul, South Korea. The event has established itself as the most targeted biologics and biosimilars-focused platform in Korea that brings together Korean and international biopharma leaders, innovative biotechs, and technocrats to convene and discuss on strategies, latest technologies and best practices.

The global biologics market is valued at an estimated $149 billion and is expected to reach $230 billion by 2015. South Korea's biologics industry, with life science companies such as Celltrion, Samsung Biologics and LG Life Sciences, is well positioned to tap into this growing market. Furthermore, innovative firms in South Korea such as Genexine, PharmAbcine, Alteogen and Ildong are building up an impressive innovative biologic pipeline that can rival international players.

The biologics landscape in South Korea is evolving at a rapid pace and getting to know the prominent players of the industry are crucial to stay competitive. Biologics World Korea 2013 conference will convene all these biologic players from South Korea and around the globe to discuss the trend and challenges in biologic drug development.

The conference will be chaired by Dr Byeong Doo Song, president, Scripps Korea Antibody Institute. The conference will feature several eminent speakers, including Dr Stanley Hong, president, R&D, Celltrion, and Dr Paul Coleman, CEO, Hanwha Biologics, among others.

The 2013 conference programme will feature industry visionary presentations from the Celltrion, Hanwha Biologics, Green Cross, Genexine, SK Chemicals, CJ CheilJedang, Mogam Biotech Institute, UCB Korea, Neopharm, KAIST, KRIBB, KBSI, PhamAbcine, Creagene, Merck Serono, Protein Science Corporation, NovImmune, Actokine, Quest Pharma Tech, Wuxi AppTech Biologics and many more. Technology providers such as BD Bioscience, Waters Korea, Dong-Il Shimadzu, Agilent Technologies and many others will also be there to showcase the latest solutions.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls